Takeda Oncology
Yaoyao Shi is a seasoned professional in the field of translational research and immunology, currently serving as the Translational Research Lead at Takeda Oncology since September 2022. Prior experience includes roles as a Senior Scientist in Cell Therapy Clinical Biomarker at Athenex, and as a Scientist II at Ziopharm Oncology, where efforts focused on preclinical studies for TCR-T cell therapeutics. Notably, Yaoyao Shi has contributed to clinical biomarker discovery and immune monitoring at MD Anderson Cancer Center, and conducted impactful preclinical research on antibody therapeutics during a postdoctoral fellowship at the University of Chicago Medicine. Yaoyao Shi holds a Ph.D. in Immunology from the Chinese Academy of Sciences and completed a postdoctoral fellowship in Radiation and Cellular Oncology at the University of Chicago.
Takeda Oncology
20 followers
In 2008, Takeda Pharmaceutical Company Limited acquired Millennium Pharmaceuticals and the resulting company became exclusively focused on oncology. In 2014, Takeda Oncology was created to become the global headquarters for Takeda’s oncology specialty business unit, in Cambridge, Massachusetts, on the former Millennium Pharmaceuticals site. AtTakeda Oncology they endeavor to deliver novel medicines to patients with cancer worldwide through our commitment to science, breakthrough innovation and passion for improving the lives of patients. This singular focus drives our aspirations to discover, develop and deliver breakthrough oncology therapies. By concentrating the power of leading scientific minds and the vast resources of a global pharmaceutical company, they are finding innovative ways to improve the treatment of cancer.They've built a portfolio of paradigm-changing therapies and a leading oncology pipeline. Though They've made great strides in our fight against cancer, they are determined to do more — to work harder and to reach higher. They continue to seek our aspirations with the same passion, agility and entrepreneurial spirit that has sustained our patient-centric culture and has made us the leaders in oncology that they are today.